Trading- und Aktien-Chat Forum: Community User: ÄffchenNotToGo

Canadian National Railway reported a rise in third-quarter profit and revenue thanks to higher freight volumes transported. The Canadian railroad on Friday posted higher net income of 1.14 billion Canadian dollars ($815 million), or C$1.83 a share, up from C$1.09 billion, or C$1.72 a share, in the comparable quarter a year earlier. Adjusted earnings were C$1.83 a share, coming in ahead of the C$1.77 a share that analysts expected for the period, according to a FactSet poll. Total revenue rose in the quarter, reaching C$4.17 billion from C$4.11 billion a year earlier, just ahead of Wall Street expectations of a rise to C$4.16 billion. Freight revenue rose to C$3.99 billion from C$3.92 billion. CN Rail operates a nearly 20,000-mile rail network and related transportation services, connecting Canada's eastern and western coasts with the U.S. Midwest and the U.S. Gulf Coast. On the operations side, gross ton miles increased 1% to 111.9 billion and revenue ton miles also rose 1% to 57.19 billion. GTM represents the total weight of a train multiplied by the distance traveled in miles, while RTM, a financial metric, is the weight of revenue-generating freight multiplied by the distance. Operating ratio, which measures efficiency, was 61.4%, down by 170 basis points from a year earlier. In this metric, a lower ratio indicates better profitability. For the year, Montreal-based CN Rail said it would keep its guidance unchanged, calling for mid- to high-single-digit adjusted earnings-per-share growth. It also said it continues to invest net of about C$3.35 billion in its capital program.. @Ascadian

Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational Basis; Global Vraylar Net Revenues Were $934 Million; Global Botox Therapeutic Net Revenues Were $985 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $642 Million Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.682 Billion, a Decrease of 0.3 Percent on a Reported Basis, or 1.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $706 Million; Global Venclexta Net Revenues Were $726 Million; Global Elahere Net Revenues Were $170 Million Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.193 Billion, a Decrease of 3.7 Percent on a Reported Basis, or 4.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $253 Million Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65, which Includes an Unfavorable Impact of $2.05 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025 Announces 2026 Dividend Increase of 5.5 Percent, Beginning with Dividend Payable in February 2026